Ovarian, Fallopian, Peritoneal Cancer Study
GOG 126R: A Phase II Evaluation Of Abraxane In The Treatment Of Recurrent Or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Protocol ID
Protocol Description
The purpose of this study is to find out if Abraxane® works in treating ovarian, fallopian tube, or primary peritoneal cancer and to find out what side effects are caused by treatment with this drug.
Abraxane® is a modified form of paclitaxel, a drug which has shown effectiveness in treating ovarian, uterine, and cervical cancer. Abraxane® is being developed to reduce the side effects that go along with paclitaxel treatment. Abraxane® is FDA-approved for the treatment of breast cancer.
Eligibility Criteria
Patients with ovarian, fallopian tube, or primary peritoneal cancer that has failed to respond to initial chemotherapies, has re-grown after surgery, radiation therapy, or other forms of treatment
Primary Investigator(s)
- Veena John, MD